Webinar
Drug repurposing represents a potentially rich source of new therapies because it involves the use of de-risked medicines that are already available to patients. The possible advantages of this approach include lower overall development costs and shorter development timelines, as well as economic and societal benefits for more sustainable healthcare systems in the long term.
However, to crystallise these benefits significant challenges need to be addressed. These include overcoming regulatory hurdles, demonstrating utility and achieving the appropriate endpoint to allow best access for patients.
To help charities and researchers devise their own strategies to repurpose drugs, LifeArc, supported by Pinsent Masons, is holding a seminar with a number of experts in the field to discuss issues such as intellectual property, regulation, commercial positioning and patient involvement.
09:30 |
Attendees invited to join and set up |
10:00 |
Welcome and introductions LifeArc |
10:05 |
Scene Setting - Repurposing existing drugs for Rare Diseases Jo Pisani - LifeArc |
10:20 |
The charity view Anne Lennox - Myotubular Trust |
10:35 |
Regulatory considerations Dan O'Connor - MHRA |
10:50 |
Intellectual Property and Patents Nicole Jadeja - Pinsent Masons |
11:05 |
The role of generics companies Paul Fleming - BGMA |
11:20 |
Break |
11:30 |
Market access Rob Whitmore - Roboleo & Co |
11:45 |
Case studies - Tay-Sachs, Nieman Pick Taylor Fields - Intrabio |
12:00 |
Q&A and meeting close
|
Anne Lennox
Founding Trustee at Myotubular Trust
Dan O’Connor
Medical Assessor at MHRA
Jo Pisani
Trustee at LifeArc
Paul Fleming
Technical Director at BGMA
Rob Whitemore
Founder/Owner at Roboleo & Co Ltd
Taylor Fields
Senior Vice President at IntraBio